Nkarta (NKTX) Total Current Liabilities (2019 - 2026)
Nkarta (NKTX) posted quarterly Total Current Liabilities of $18.2 million for Q1 2026, down 2.93% year-over-year from $18.8 million in Q1 2025, and down 18.23% quarter-over-quarter from $22.3 million in Q4 2025.
Nkarta (NKTX) Total Current Liabilities (2019 - 2026) Analysis & Trends
Nkarta's Total Current Liabilities history runs 8 years deep, the most recent figure standing at $18.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 2.93% year-over-year to $18.2 million; the TTM figure through Mar 2026 stood at $18.2 million (down 2.93% YoY), while the FY2025 annual figure was $22.3 million, up 17.7% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $18.2 million, down from $22.3 million in the prior quarter.
- The five-year high for Total Current Liabilities was $26.6 million in Q2 2023, with the low at $10.8 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $22.0 million (2022), against an average of $20.9 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 139.63% in 2023, then fell 21.61% in 2024.
- Nkarta's Total Current Liabilities stood at $22.0 million in 2022, then climbed by 5.82% to $23.3 million in 2023, then retreated by 18.92% to $18.9 million in 2024, then increased by 17.7% to $22.3 million in 2025, then decreased by 18.23% to $18.2 million in 2026.
- Business Quant data shows NKTX's Total Current Liabilities at $18.2 million in Q1 2026, $22.3 million in Q4 2025, and $19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 23.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.56 Mn |
| Mar 31, 2026 | 18.21 Mn |
| Dec 31, 2025 | 22.27 Mn |
| Sep 30, 2025 | 18.99 Mn |
| Jun 30, 2025 | 18.93 Mn |
| Mar 31, 2025 | 18.76 Mn |
| Dec 31, 2024 | 18.92 Mn |
| Sep 30, 2024 | 22.47 Mn |
| Jun 30, 2024 | 20.86 Mn |
| Mar 31, 2024 | 22.19 Mn |
| Dec 31, 2023 | 23.33 Mn |
| Sep 30, 2023 | 25.64 Mn |
| Jun 30, 2023 | 26.61 Mn |
| Mar 31, 2023 | 25.98 Mn |
| Dec 31, 2022 | 22.05 Mn |
| Sep 30, 2022 | 26.43 Mn |
| Jun 30, 2022 | 13.18 Mn |
| Mar 31, 2022 | 10.84 Mn |
| Dec 31, 2021 | 12.94 Mn |
| Sep 30, 2021 | 12.05 Mn |